MEDIASSISTFinancial Services

Medi Assist Healthcare Services Limited

Insurance Distributors · ISIN INE456Z01021 · BSE 544088 · NSE EQ · FV ₹5
Last price
₹321
+2.77%today
What this company does

Medi Assist Healthcare Services Limited operates in Insurance Distributors, part of the Financial Services sector. It booked ₹237 cr of revenue in its latest quarter (Q1 FY27) and kept 11.7% of sales as profit.

In the report:
53out of 100
Equitytale Health Score
Mixed

Healthier than 53% of companies in Financial Services, on the 4 of 6 measures we could read for it. Each measure is ranked against the 54–250 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
39

At close. Not part of the score.

Profitability & returns47

How much profit it earns on the money it employs

Cash quality88

Whether reported profit actually arrives as cash

Valuation31

What today's price implies, against our models or its peers

Governance & risk72

How much of the promoters' stake is pledged, and how much they hold

Not measurable for this company: balance sheet, growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Strengths
Makes a profit
Sales up 24% vs last year
Profit up 24% vs last year
No promoter shares pledged
Virtually debt-free
Watch-outs
! Operating cash flow is negative

What if I invest in MEDIASSIST?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹321 +2.77%
latest close · 2026-09-17
52-wk low ₹30842 sessions so far52-wk high ₹376
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio21.6Average
LowAverageHigh
P/B ratio2.86Moderate
Below bookModerateHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity13.2%Fair
WeakFairStrong ▸15%
Return on capital15.7%Strong
WeakFairStrong
Net margin11.7%Decent
ThinDecentStrong
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.00Comfortable
LowModerateHigh ▸1
Current ratio1.34Healthy
Tight ◂1HealthyAmple
More figures
Market cap
₹2,399 cr
Book value
₹112
EPS
₹3.71
latest quarter
Net debt
Enterprise value
EBITDA
EBIT
Operating margin
Return on assets
8.1%
Earnings yield
4.62%
P/S
2.54
Sales / share
₹126.6
Tax rate
20.9%
Face value
₹5
Shares
7.5 cr
Working capital
₹148 cr
Current assets
₹585 cr
Current liabilities
₹438 cr
Delivery %
58.4%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2024 report & filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹84₹172, midpoint ₹110

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹237 cr
Other Income₹10 cr
Total Income₹247 cr
Cost of Materials₹0 cr
Purchases of Stock-in-Trade₹0 cr
Employee Benefit Expense₹103 cr
Finance Costs₹2 cr
Depreciation & Amortisation₹22 cr
Other Expenses₹85 cr
Total Expenses₹212 cr
Profit before Tax₹35 cr
Tax Expense₹7 cr
Net Profit₹28 cr
Net margin on total income11.2%
Where the money goes · Q1 FY27
% of total income
Employee benefit expense₹103 cr41.8%
Finance costs₹2 cr0.7%
Depreciation & amortisation₹22 cr8.8%
Other expenses₹85 cr34.5%
Tax expense₹7 cr3.0%
Profit for the period₹28 cr11.2%
Total income ₹247 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue240 cr242 cr237 cr
Total income247 cr243 cr247 cr
Expenses225 cr215 cr212 cr
Profit before tax8 cr28 cr35 cr
Tax4 cr-27 cr7 cr
Net profit (owners' share)4 cr53 cr28 cr
Net margin (owners' share, on revenue)1.7%22.1%11.7%
EPS (₹)0.517.333.71
YoY (latest quarter): total income +24.8% · net profit +23.6%
Balance sheet & cash flow · as of Mar 2026
Debt-free
Total assets
₹1,372 cr
Shareholder equity
₹839 cr
parent shareholders
Total debt
₹0 cr
Cash
₹55 cr
Cash flow · H1 FY26
Operating
₹-13 cr
Investing
₹-88 cr
Financing
₹74 cr
Peer comparison
Financial Services · by market value (sector-level match)
CompanyPriceMarket capP/E
HDFC Bank Limited₹713₹10.98 L cr14.3
ICICI Bank Limited₹1,348₹9.67 L cr15.6
State Bank of India₹989₹9.13 L cr9.5
Bajaj Finance Limited₹1,015₹6.31 L cr26.4
Bajaj Finserv Limited₹1,859₹5.97 L cr23.7
Kotak Mahindra Bank Limited₹417₹4.14 L cr18.9
Axis Bank Limited₹1,240₹3.86 L cr12.6
Shriram Finance Limited₹995₹2.34 L cr16.7
ICICI Prudential Asset Management Company Limited₹3,098₹1.53 L cr39.7
Same sector · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
0.62%
trailing 12 months
Dividend / share (TTM)
₹2
Last dividend
₹2
ex 11 Sep 2026
ActionDetailEx-date
Dividend₹2 / share11 Sep 2026
Dividend₹4 / share6 Sep 2024
Who owns it · 2026-06-30
No pledge
Promoter
4.6%
FII / Foreign
25.4%
DII / Domestic
47.2%
Retail / others
22.7%
Promoter stake down 35.1% over the last 12 quarters.
Smart-money activity
Bulk / block deals
BoughtNTASIAN DISCOVERY MASTER FUND · NSE4.00 L @ ₹356.7625 Aug 26
short · NSE32712 May 26
short · NSE4752 Apr 26
Stake changes
SoldHDFC Mutual Fund→ 5.59% · 11.90 L20 Jul 26
Bought238 PLan→ 1.67% · 4.24 L3 Jul 26
BoughtMIT→ 5.63% · 12.79 L3 Jul 26
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Postal ballot · 24 Feb 2026
See the official result
1
Approval for re-appointment of Dr. Ritu Niraj Anand (DIN: 00363699) as an Independent Director of the Company for the second term of five years from March 15, 2026 to March 14, 2031 (both days inclusive)
Backed by 100% of shareholders other than promotersneeded 75%
5.01 cr votes for, 4,978 against · 0% of mutual funds and other big investors said no
2
Approval for re-appointment of Dr. Vikram Jit Singh Chhatwal (DIN: 01606329) as the Chairman and Whole-Time Director of the Company for a further period of five years with effect from March 01, 2026 to February 28, 2031 (both days inclusive)
Backed by 99% of shareholders other than promotersneeded 50%
4.94 cr votes for, 7.30 L against · 1% of mutual funds and other big investors said no
3
Approval of remuneration payable to Dr. Vikram Jit Singh Chhatwal (DIN: 01606329), Chairman and Whole-Time Director of the Company for a period not exceeding three years effective from March 01, 2026
Backed by 99% of shareholders other than promotersneeded 75%
4.94 cr votes for, 7.30 L against · 1% of mutual funds and other big investors said no
4
Approval for re-appointment of Mr. Satish V N Gidugu (DIN: 06643677) as the Whole-Time Director and Chief Executive Officer of the Company for a further period of five years with effect from March 01, 2026 to February 28, 2031 (both days inclusive)
Backed by 100% of shareholders other than promotersneeded 50%
4.99 cr votes for, 2.10 L against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 17 named members
owning 4.6% between them · as of 2026-06-30
Medimatter Health Management Private Limited4.61%
Ashok Kumar Choudhuryno shares
Geetali Chhatwal Jonssonno shares
Harita Guptano shares
Major General M J S Chhatwal HUFno shares
Manas Factories Combine (Private) Limitedno shares
Manas Products (Protein) Private Limitedno shares
Manas Tradersno shares
Business done with them
FY2025 · 3 of the group
The company paid ₹6 cr to companies in the promoter group last year — about 0.9% of its ₹723 cr revenue.
Vikram Jit Singh Chhatwal
Other payments to them · Reimbursement of charges from Promoter, Employee benefit payables & Reimbursement of expense to Director
₹4 cr
company paid
MEDIMATTER HEALTH MANAGEMENT PRIVATE LIMITED
Other payments to them · Reimbursement of charges from Promoter
also owns 4.61% of the company
₹2 cr
company paid
Bessemer Health Capital LLC
Other payments to them · Reimbursement of charges from Promoter
₹99.5 L
company paid

The company also transacted with 16 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹198 cr raised in Oct 2025 by selling shares to selected investors

As of Jun 2026, the company says it has spent 77% of what it set aside, leaving ₹45 cr still to be spent. CARE Ratings Limited watches the spending on the exchange’s behalf.

For undertaking investment in Medi Assist Insurance TPA Pvt. Limited, a wholly-owned material subsidiary of the Company (“Subsidiary”), in the form of equity/quasi equity, debt/loan instruments, which will be utilized by the Subsidiary to prepay/repay, in full or part, all or a portion of certain outstanding borrowings availed by the Subsidiary from banks, nonbanking finance companies and other lenders, if any. (“Investment in Subsidiary for Debt Prepayment/ Repayment”)
99%
₹148 cr of ₹150 cr
Up to 25% (twenty-five percent) of the Issue Proceeds will be utilised for general corporate purposes, which includes, inter alia, meeting ongoing general corporate exigencies and contingencies, expenses and investments of the Company as applicable in such a manner and proportion as may be decided by the Board from time to time, and/or any other general purposes as may be permissible under applicable laws (“General Corporate Purposes”)
10%
₹5 cr of ₹48 cr
Spent by quarter: 75%75%77% (to Jun 2026)

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.